Cargando…
Progenitor Cell Therapy for the Treatment of Central Nervous System Injury: A Review of the State of Current Clinical Trials
Recent preclinical work investigating the role of progenitor cell therapies for central nervous system (CNS) injuries has shown potential neuroprotection in the setting of traumatic brain injury (TBI), spinal cord injury (SCI), and ischemic stroke. Mechanisms currently under investigation include en...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
SAGE-Hindawi Access to Research
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956462/ https://www.ncbi.nlm.nih.gov/pubmed/21048846 http://dx.doi.org/10.4061/2010/369578 |
_version_ | 1782188147878133760 |
---|---|
author | Walker, Peter A. Harting, Matthew T. Shah, Shinil K. Day, Mary-Clare El Khoury, Ramy Savitz, Sean I. Baumgartner, James Cox, Charles S. |
author_facet | Walker, Peter A. Harting, Matthew T. Shah, Shinil K. Day, Mary-Clare El Khoury, Ramy Savitz, Sean I. Baumgartner, James Cox, Charles S. |
author_sort | Walker, Peter A. |
collection | PubMed |
description | Recent preclinical work investigating the role of progenitor cell therapies for central nervous system (CNS) injuries has shown potential neuroprotection in the setting of traumatic brain injury (TBI), spinal cord injury (SCI), and ischemic stroke. Mechanisms currently under investigation include engraftment and transdifferentiation, modulation of the locoregional inflammatory milieu, and modulation of the systemic immunologic/inflammatory response. While the exact mechanism of action remains controversial, the growing amount of preclinical data demonstrating the potential benefit associated with progenitor cell therapy for neurological injury warrants the development of well-controlled clinical trials to investigate therapeutic safety and efficacy. In this paper, we review the currently active or recently completed clinical trials investigating the safety and potential efficacy of bone marrow-derived progenitor cell therapies for the treatment of TBI, SCI, and ischemic stroke. Our review of the literature shows that while the preliminary clinical trials reviewed in this paper offer novel data supporting the potential efficacy of stem/progenitor cell therapies for CNS injury, a great deal of additional work is needed to ensure the safety, efficacy, and mechanisms of progenitor cell therapy prior to widespread clinical trials. |
format | Text |
id | pubmed-2956462 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | SAGE-Hindawi Access to Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-29564622010-11-03 Progenitor Cell Therapy for the Treatment of Central Nervous System Injury: A Review of the State of Current Clinical Trials Walker, Peter A. Harting, Matthew T. Shah, Shinil K. Day, Mary-Clare El Khoury, Ramy Savitz, Sean I. Baumgartner, James Cox, Charles S. Stem Cells Int Review Article Recent preclinical work investigating the role of progenitor cell therapies for central nervous system (CNS) injuries has shown potential neuroprotection in the setting of traumatic brain injury (TBI), spinal cord injury (SCI), and ischemic stroke. Mechanisms currently under investigation include engraftment and transdifferentiation, modulation of the locoregional inflammatory milieu, and modulation of the systemic immunologic/inflammatory response. While the exact mechanism of action remains controversial, the growing amount of preclinical data demonstrating the potential benefit associated with progenitor cell therapy for neurological injury warrants the development of well-controlled clinical trials to investigate therapeutic safety and efficacy. In this paper, we review the currently active or recently completed clinical trials investigating the safety and potential efficacy of bone marrow-derived progenitor cell therapies for the treatment of TBI, SCI, and ischemic stroke. Our review of the literature shows that while the preliminary clinical trials reviewed in this paper offer novel data supporting the potential efficacy of stem/progenitor cell therapies for CNS injury, a great deal of additional work is needed to ensure the safety, efficacy, and mechanisms of progenitor cell therapy prior to widespread clinical trials. SAGE-Hindawi Access to Research 2010-07-20 /pmc/articles/PMC2956462/ /pubmed/21048846 http://dx.doi.org/10.4061/2010/369578 Text en Copyright © 2010 Peter A. Walker et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Walker, Peter A. Harting, Matthew T. Shah, Shinil K. Day, Mary-Clare El Khoury, Ramy Savitz, Sean I. Baumgartner, James Cox, Charles S. Progenitor Cell Therapy for the Treatment of Central Nervous System Injury: A Review of the State of Current Clinical Trials |
title | Progenitor Cell Therapy for the Treatment of Central Nervous System Injury: A Review of the State of Current Clinical Trials |
title_full | Progenitor Cell Therapy for the Treatment of Central Nervous System Injury: A Review of the State of Current Clinical Trials |
title_fullStr | Progenitor Cell Therapy for the Treatment of Central Nervous System Injury: A Review of the State of Current Clinical Trials |
title_full_unstemmed | Progenitor Cell Therapy for the Treatment of Central Nervous System Injury: A Review of the State of Current Clinical Trials |
title_short | Progenitor Cell Therapy for the Treatment of Central Nervous System Injury: A Review of the State of Current Clinical Trials |
title_sort | progenitor cell therapy for the treatment of central nervous system injury: a review of the state of current clinical trials |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956462/ https://www.ncbi.nlm.nih.gov/pubmed/21048846 http://dx.doi.org/10.4061/2010/369578 |
work_keys_str_mv | AT walkerpetera progenitorcelltherapyforthetreatmentofcentralnervoussysteminjuryareviewofthestateofcurrentclinicaltrials AT hartingmatthewt progenitorcelltherapyforthetreatmentofcentralnervoussysteminjuryareviewofthestateofcurrentclinicaltrials AT shahshinilk progenitorcelltherapyforthetreatmentofcentralnervoussysteminjuryareviewofthestateofcurrentclinicaltrials AT daymaryclare progenitorcelltherapyforthetreatmentofcentralnervoussysteminjuryareviewofthestateofcurrentclinicaltrials AT elkhouryramy progenitorcelltherapyforthetreatmentofcentralnervoussysteminjuryareviewofthestateofcurrentclinicaltrials AT savitzseani progenitorcelltherapyforthetreatmentofcentralnervoussysteminjuryareviewofthestateofcurrentclinicaltrials AT baumgartnerjames progenitorcelltherapyforthetreatmentofcentralnervoussysteminjuryareviewofthestateofcurrentclinicaltrials AT coxcharless progenitorcelltherapyforthetreatmentofcentralnervoussysteminjuryareviewofthestateofcurrentclinicaltrials |